Related Experiment Video
Updated: May 23, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Oncologists experience with second primary cancer screening: current practices and barriers and potential solutions
Dong Wook Shin1, Yeol Kim, Young Ji Baek
1Department of Family Medicine and Health Promotion Center, Seoul National University Hospital, Seoul, South Korea.
Asian Pacific Journal of Cancer Prevention : APJCP
|April 25, 2012
Summary
Oncologists rarely promote second primary cancer (SPC) screening, viewing it as unplanned care. Barriers include time, knowledge gaps, and lack of guidelines, necessitating shared care models for improved cancer survivorship.
Area of Science:
- Oncology
- Cancer Survivorship
- Public Health
Background:
- Second primary cancer (SPC) screening is vital for cancer survivorship care.
- Understanding oncologists' perspectives on promoting SPC screening is crucial.
Purpose of the Study:
- To explore oncologists' experiences and challenges in promoting second primary cancer screening among cancer survivors.
Main Methods:
- Qualitative study involving two focus group interviews with 12 oncologists.
- Thematic analysis was used to identify recurrent issues and categorize findings.
Main Results:
- Most oncologists do not consider SPC screening promotion a routine responsibility.
- SPC screening is often reactive, prompted by patient requests, not proactive.
- Key barriers include short consultation times, limited knowledge, lack of guidelines, and role ambiguity.
Conclusions:
- Oncologists face challenges in managing and promoting SPC screening effectively.
- Lack of knowledge, resources, and guidelines hinders proactive SPC screening.
- Shared care models and increased oncologist involvement are recommended for better SPC screening promotion in cancer survivors.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:30Preventive Healthcare Services
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...